-+ 0.00%
-+ 0.00%
-+ 0.00%

ALX Oncology publishes 2025 annual report

PUBT·04/23/2026 02:55:30
Listen to the news
ALX Oncology publishes 2025 annual report
  • ALX Oncology annual report for fiscal 2025 highlighted continued focus on two clinical-stage programs, CD47 blocker evorpacept, EGFR-targeted ADC ALX2004.
  • Evorpacept strategy shifted toward combinations with Fc-active anti-cancer antibodies to drive antibody-dependent cellular phagocytosis, supported by experience in 800+ patients across more than a dozen trials.
  • Biomarker work presented in 2025, reinforced by Phase 1 top-line results in early 2026, linked responses in HER2-positive gastric cancer, HER2-positive breast cancer largely to high CD47 expression.
  • ASPEN-09-Breast Phase 2 remained on track for mid-2027 top-line data in 80 patients, with enrollment progressing globally.
  • ALX2004 Phase 1 dose escalation cleared first two cohorts, with full safety data from dose escalation expected in second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.